Zydus receives final approval from the USFDA for Mesalamine Suppositories for rectal use, 1000 mg

Zydus receives final approval from the USFDA for Mesalamine Suppositories for rectal use, 1000 mg Ahmedabad, 13 February, 2020 Zydus Cadila has received the final approval from the USFDA to market Mesalamine Suppositories for rectal use, (US RLD - Canasa) 1000 mg. The drug is used to treat ulcerative proctitis, a type of bowel disease. It is an aminosal icylate anti-inflammatory drug and believed to work by blocking the production of certain natural chemicals that may cause pain and swelling. This will be manufactured at the group’s Topical manufacturing facility at Ahmedabad. The group now has 280 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗